Clinical trials: Gastric Cancer, Metastatic
Liver, Metastasis
Neo-adjuvant Peptide Receptor Mediated Radiotherapy With 177Lutetium in Front of Curative Intended Liver Transplantation in Patients With Hepatic Metastasis of Neuroendocrine Tumors (NEO-LEBE)
The purpose of this study is to show the tumor free long term survival of patients with isolated non-resectable liver metastases of neuroendocrine tumors after neo-adjuvant radio receptor treatment and following liver…
- Conditions
- Liver, Metastasis, Neuroendocrine Tumors
- Trial name
- NEO-LEBE (NCT01201096)
- Testing
- 177Lutetium, Liver transplantation
- Where
- 2 sites in Germany
- Volunteers
- 50 people
- Sponsor
- University of Jena
Gastrointestinal Epithelial Cancer, Gastrointestinal Neoplasms
A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering
A clinical trial to assess the safety and efficacy of genetically-engineered, neoantigen-specific Tumor Infiltrating Lymphocytes (TIL) in which the intracellular immune checkpoint CISH has been inhibited using CRISPR gene editing…
- Conditions
- Gastrointestinal Epithelial Cancer, Gastrointestinal Neoplasms, Cancer of Gastrointestinal Tract, Cancer, Gastrointestinal
- Trial name
- NCT04426669
- Testing
- Cyclophosphamide, Fludarabine, Tumor-Infiltrating Lymphocytes (TIL)
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Intima Bioscience, Inc.
Gastric Cancer, Metastatic
The Efficacy of Surgical Treatment After Neoadjuvant Chemotherapy Plus Intraperitoneal Immunotherapy Versus Chemotherapy Alone for Patients With Positive Wash Cytology Gastric Cancer
The purpose of this study is to determine whether intraperitoneal immunotherapy (with interleykin-2 - human cytokine reaction activator) with systemic chemotherapy will be more effective than systemic chemotherapy alone in…
- Trial name
- NCT02976142
- Testing
- neoadjuvant chemoimmunotherapy
- Volunteers
- 150 people
- Sponsor
- Moscow Clinical Scientific Center
Metastatic Gastric Cancer
An Open Label, Prospective, Multicentre, Non-interventional Study of Apatinib for Chemotherapy-Refractory Advanced Metastatic Gastric Cancer
This is an Open Label, Prospective, Multicentre, Non-interventional Study of Apatinib for Chemotherapy-Refractory Advanced Metastatic Gastric Cancer, the investigators opted to give patients for apatinib 850 mg once daily, 28…
- Trial name
- AHEAD-G202 (NCT02668380)
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Peking Union Medical College Hospital
NSCLC Adenocarcinoma, Gastroesophageal Cancer (GC)
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
This is a multicenter clinical study to evaluate the safety, efficacy, and Pharmacokinetics (PK) of IDE892 as monotherapy and in combination with other agents including IDE397 in participants with methylthioadenosine…
- Conditions
- NSCLC Adenocarcinoma, Gastroesophageal Cancer (GC), Gastric Adenocarcinoma, Adenocarcinoma of Esophagus
- Trial name
- NCT07277413
- Testing
- IDE892, IDE397
- Where
- 23 sites in United States
- Volunteers
- 260 people
- Sponsor
- IDEAYA Biosciences
Gastric Cancer
Fluorouracil, Oxaliplatin, and Leucovorin in Treating Patients With Metastatic Stomach Cancer or Gastroesophageal Junction Cancer
RATIONALE: Drugs used in chemotherapy, such as fluorouracil, oxaliplatin, and leucovorin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00514020
- Testing
- fluorouracil, leucovorin calcium, oxaliplatin
- Where
- 5 sites in United States
- Volunteers
- 33 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Diffuse Adenocarcinoma of the Stomach, Intestinal Adenocarcinoma of the Stomach
S0413 Lapatinib in Treating Patients With Locally Advanced or Metastatic Stomach Cancer
This phase II trial is studying how well lapatinib works in treating patients with locally advanced or metastatic stomach cancer. Lapatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth
- Conditions
- Diffuse Adenocarcinoma of the Stomach, Intestinal Adenocarcinoma of the Stomach, Mixed Adenocarcinoma of the Stomach, Recurrent Gastric Cancer
- Trial name
- NCT00103324
- Testing
- lapatinib ditosylate, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
GastroEsophageal Cancer
Trial of Lapatinib Versus Lapatinib With Capecitabine in Her2+ Metastatic Gastro-Esophageal Cancer
Combining Erb inhibitors, such lapatinib, and TS inhibitors, such as capecitabine, may be a beneficial contribution to current treatment paradigms since preclinical data suggest that lapatinib alone can decrease TS mRNA and is…
- Trial name
- GastroLap (NCT01145404)
- Testing
- Lapatinib, Lapatinib plus capecitabine
- Where
- 16 sites in Germany
- Volunteers
- 76 people
- Sponsor
- National Center for Tumor Diseases, Heidelberg
Gastric Adenocarcinoma, Metastatic Adenocarcinoma of the Gastroesophageal Junction
Ramucirumab Plus TAS-102 in Patients With Advanced or Metastatic Gastric Adenocarcinoma or the Gastroesophageal Junction
The objective of this study is to determine whether a combination of ramucirumab, beyond progression after a SOC 2nd line ramucirumab based pre-treatment (Ram beyond progression) in patients with locally advanced or metastatic…
- Trial name
- RE-ExPEL (NCT04517747)
- Testing
- Ramucirumab, TAS 102
- Where
- 5 sites in Germany
- Volunteers
- 20 people
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Gastric Cancer
Study of Convernsion Therapy Using S1/Paclitaxel Chemotherapy Plus Apatinib in Unresectable Gastric Cancer
The prognosis of metastatic gastric cancer is poor. Chemotherapy occasionally converts an initially unresectable gastric cancer to a resectable cancer.
- Trial name
- NCT02529878
- Testing
- S1/Paclitaxel chemotherapy plus Apatinib
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- The First Affiliated Hospital of Zhejiang Chinese Medical University
HER-2 Positive Gastric Cancer, Metastatic Cancer
Herzuma-capecitabine/Cisplatin for Gastric Cancer
Stomach cancer is the fifth largest cancer in the world. Despite many combinations of studies, metastatic stomach cancer shows a median survival period of 10 to 12 months.
- Trial name
- HERZUMA-GC (NCT03588533)
- Testing
- Trastuzumab, Capecitabine, Cisplatin
- Where
- South Korea
- Volunteers
- 50 people
- Sponsor
- Sung Yong Oh
Gastric or Gastroesophageal Junction Adenocarcinoma
The Efficacy and Safety of LM-302 in Combination With Candonilimab and Capecitabine for First-Line Treatment in Patients With Unresectable Advanced, Recurrent, or Metastatic CLDN18.2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma
A Phase II Study Evaluating the Efficacy and Safety of LM-302 in Combination with Candonilimab and Capecitabine for First-Line Treatment in Patients with Unresectable Advanced, Recurrent, or Metastatic CLDN18.2-Positive Gastric…
- Trial name
- NCT06587425
- Testing
- LM-302+Candonilimab+Capecitabine
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Shanghai Zhongshan Hospital
Gastrointestinal Stromal Tumors
Masitinib in First Line Treatment of Gastro-Intestinal Stromal Tumor (GIST)
Masitinib in First Line Treatment of Gastro-Intestinal Stromal Tumor (GIST)
- Trial name
- NCT00812240
- Testing
- Masitinib, Imatinib
- Where
- 41 sites in United States, France and 1 more
- Volunteers
- 335 people
- Sponsor
- AB Science
Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction, Gastric Neoplasm
Trial of S-1 Maintenance Therapy in Metastatic Esophagogastric Cancer
The aim is to assess the relative efficacy of S-1 de-escalation therapy vs. continuation of chemotherapy after induction therapy in patients with metastatic esophagogastric cancer in terms of overall survival.
- Conditions
- Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction, Gastric Neoplasm, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma
- Trial name
- MATEO (NCT02128243)
- Testing
- S-1 de-escalation, Chemotherapy by Investigator's choice
- Where
- Germany
- Volunteers
- 242 people
- Sponsor
- AIO-Studien-gGmbH
Advanced Solid Tumor, Melanoma
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
This is a proof-of-concept study designed to investigate HER3-DXd monotherapy in locally advanced unresectable or metastatic solid tumors.
- Conditions
- Advanced Solid Tumor, Melanoma, Head and Neck Cancer, Gastric Cancer
- Trial name
- NCT06172478
- Testing
- HER3-DXd
- Where
- 96 sites in United States, Australia and 14 more
- Volunteers
- 740 people
- Sponsor
- Daiichi Sankyo
Gastric Cancer, Metastatic
The Efficacy and Safety of HIPEC Combined With PD-1 and SOX Chemotherapy for the Translational Treatment of GC or EGJC With PM
Gastric cancer (GC) with peritoneal metastasis has a poor prognosis and short survival. In recent years, heat intraperitoneal perfusion chemotherapy (HIPEC) has gained better efficacy in the treatment of peritoneal metastases of…
- Trial name
- NCT06427252
- Testing
- HIPEC, Systemic therapy
- Where
- China
- Volunteers
- 50 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Esophageal Cancer, Gastric Cancer
BMS-247550 in Treating Patients With Metastatic Stomach Cancer Previously Treated With Chemotherapy
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of BMS-247550 in treating patients who have metastatic…
- Trial name
- NCT00017043
- Testing
- ixabepilone
- Where
- United States
- Sponsor
- Bristol-Myers Squibb
Gastric Cancer
Acupuncture Combined With Chemotherapy for Gastric Cancer After Surgery
This multicenter, randomized, parallel-group clinical trial aims to evaluate the efficacy of acupuncture combined with adjuvant chemotherapy in patients with gastric cancer who have undergone surgery.
- Trial name
- NCT07098949
- Testing
- Acupuncture, Chemotherapy
- Where
- 3 sites in China
- Volunteers
- 346 people
- Sponsor
- Guangzhou University of Traditional Chinese Medicine
Adenocarcinoma of the Gastroesophageal Junction, Esophageal Undifferentiated Carcinoma
Pralatrexate and Oxaliplatin in Treating Patients With Unresectable or Metastatic Esophageal, Stomach, or Gastroesophageal Junction Cancer
This phase II trial studies how well pralatrexate and oxaliplatin work in treating patients with esophageal, stomach, or gastroesophageal junction cancer that cannot be removed by surgery or has spread from the primary site…
- Conditions
- Adenocarcinoma of the Gastroesophageal Junction, Esophageal Undifferentiated Carcinoma, Gastric Adenocarcinoma, Gastric Squamous Cell Carcinoma
- Trial name
- NCT01178944
- Testing
- Laboratory Biomarker Analysis, Oxaliplatin, Pralatrexate
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- Roswell Park Cancer Institute
Gastric Cancer, Esophageal Cancer
Study of Oxaliplatin and Xeloda and Cetuximab as First Line Treatment for Metastatic or Unresectable Gastric or Gastroesophageal Junction Cancer
This study is for people with advanced gastric or gastroesophageal cancer. This study is being done to find out how long it takes tumors to grow after patients take the drugs capecitabine, oxaliplatin and cetuximab.
- Trial name
- NCT00183898
- Testing
- oxaliplatin, capecitabine
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- University of Southern California